HSD19 Which Elements Determine Prescribing Decisions for Off-Patent Biological Medicines in Belgium? A Qualitative Study

Belgium is characterized by its low use of biosimilar products and shifts from off-patent biologicals towards new alternative therapies. Yet, prescribing decisions involved in these observations are poorly understood. This study aims to investigate prescribing choices for off-patent biologicals and biosimilars among Belgian physicians in the ambulatory care.